Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2Endocrine 2Other neoplasm 1

Conditions

Pain, Intractable 1Obesity 1Neoplasms 1Nausea 1Dyspnea 1Delirium 1Death 1

Interventions

Radiotherapy 5Surveys and Questionnaires 4Cisplatin 4angiotensin I (1-7) 3alvimopan 3Radiation 3Injections 3Water 2Vitamin D 2Tirzepatide 2RRx-001 2Mouthwashes 2Metformin 2Interleukin 1 Receptor Antagonist Protein 2High-Intensity Focused Ultrasound Ablation 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Calcium Dobesilate 2Amifostine 2Acetylcysteine 2tempol 1peppermint oil 1pegfilgrastim 1naloxegol 1methylnaltrexone 1methyl N-acetylsibirosaminide 1linaclotide 1licogliflozin 1kang-lai-te 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Dexmedetomidine × Other × Clear all
NCT04730375 2022-05-05

Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients

National Cancer Institute, Egypt

Phase 2 Completed
70 enrolled
Other

Obesity

NCT01687751 2015-05-25

Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients

Fraser Health

Phase 2 Withdrawn
Other

Death, Delirium, Dyspnea, Nausea, Neoplasms, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡